ArticleCell communication and signaling : CCS2017
LASP2 suppresses colorectal cancer progression through JNK/p38 MAPK pathway meditated epithelial-mesenchymal transition.
Article in Cell communication and signaling : CCS, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 54 citations in OpenAlex.
- Polydatin: A natural compound with multifaceted anticancer properties.Journal of traditional and complementary medicine · 2025Review
- Prognostic and immunological role of LASP2 in clear cell renal cell carcinoma.Genes & genomics · 2025Article
- RIPK2 promotes colorectal cancer metastasis by protecting YAP degradation from ITCH-mediated ubiquitination.Cell death & disease · 2025Article
- LIM and SH3 protein 2 (Lasp2) is a novel pregnane X receptor target gene in mouse liver.Molecular pharmacology · 2025Article
- LncRNA PCAT6 promotes progression and metastasis of colonic neuroendocrine carcinomaWorld journal of gastrointestinal oncology · 2025Article
- Construction of a Risk Model for Colon Cancer Prognosis Based on Ubiquitin-Related Genes.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2023Article
- A 9‑gene expression signature to predict stage development in resectable stomach adenocarcinoma.BMC gastroenterology · 2022Article
- Bioinformatics Profiling and Experimental Validation of 4 Differentially-Expressed LIM Genes in the Course of Colorectal-Adenoma-Carcinoma.Medical science monitor : international medical journal of experimental and clinical research · 2022Article
- CMTM6 as a candidate risk gene for cervical cancer: Comprehensive bioinformatics study.Frontiers in molecular biosciences · 2022Article
- CLCA2 suppresses the proliferation, migration and invasion of cervical cancer.Experimental and therapeutic medicine · 2021Article
- SOX2 promotes chemoresistance, cancer stem cells properties, and epithelial-mesenchymal transition by β-catenin and Beclin1/autophagy signaling in colorectal cancer.Cell death & disease · 2021Article
- Gene Signatures and Prognostic Values of N6-Methyladenosine Related Genes in Ovarian Cancer.Frontiers in genetics · 2021Article
- LIM-Nebulette Reinforces Podocyte Structural Integrity by Linking Actin and Vimentin Filaments.Journal of the American Society of Nephrology : JASN · 2020Article
- Galectins and Ovarian Cancer.Cancers · 2020Review
- BHLHE41 suppresses MCF-7 cell invasion via MAPK/JNK pathway.Journal of cellular and molecular medicine · 2020Article
- RCE1 deficiency enhances invasion via the promotion of epithelial-mesenchymal transition and predicts poor prognosis in hepatocellular carcinoma.American journal of translational research · 2020Article
- Antiepithelial-Mesenchymal Transition of Herbal Active Substance in Tumor Cells via Different Signaling.Oxidative medicine and cellular longevity · 2020Review
- The Expressions and Mechanisms of Sarcomeric Proteins in Cancers.Disease markers · 2020Review
- Metallopanstimulin-1 (MPS-1) mediates the promotion effect of leptin on colorectal cancer through activation of JNK/c-Jun signaling pathway.Cell death & disease · 2019Article
- Overexpression of PRDM5 promotes acute myeloid leukemia cell proliferation and migration by activating the JNK pathway.Cancer medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLASP2 (LIM and SH3 Protein 2) is a small focal adhesion protein belongs to nebulin protein family. As the newest member of nebulette family, the function of LASP2 remains to be identified.
methodsThe relationship between LASP2 expression and clinical characteristics of CRC was analyzed in 89 paraffin-embedded archived CRC specimens by immunohistochemistry (IHC). The effects of LASP2 on cell growth and migration were examined in vitro, using CCK-8 and transwell assays. Western blotting was performed to examine the impact of LASP2 on the SAPK/JNK and MAPK signaling pathways.
resultsIn the present study, we observed a decreased LASP2 expression in clinical colorectal cancer samples compared with paired normal tissues. A negative correlation was also found between LASP2 and poor prognosis of CRC patients. Gain- and loss-of-function approaches revealed that LASP2 plays inhibitory effects on the growth and migration of human CRC cells in vitro. Western-blot results showed that LASP2 could attenuate epithelial-mesenchymal transition (EMT) to accomplish its suppression on CRC aggression. In LASP2 knocked down CRC cells, EMT was inhibited along with the inactivation of JNK/p38 MAPK pathway. Consistently, treatment of JNK inhibitor (JNK inhibitor II) together with p38 inhibitor (SB203580) could resume the process of EMT. Interestingly, we found a negative relationship between LASP2 and LASP1 expression in both CRC cell lines and tumors tissues, which suggests their converse function in CRC progression.
conclusionsAll the findings indicated that LASP2 may play a significant role in suppressing CRC progression and provided a novel biomarker for CRC therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.